NCT00099047View on ClinicalTrials.gov

Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

June 30, 2008

Study Completion Date

November 30, 2008

Conditions
Monoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaSmoldering Multiple Myeloma
Interventions
DRUG

celecoxib

Given PO

DRUG

placebo

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

44195

Cleveland Clinic Foundation, Cleveland

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00099047 - Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma | Biotech Hunter | Biotech Hunter